Romiplostim - Biologic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for romiplostim
Tradenames: | 1 |
Patents: | 4 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for romiplostim |
Recent Clinical Trials for romiplostim
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Peking University People's Hospital | Phase 2 |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 3 |
Geropharm | Phase 1 |
Pharmacology for romiplostim
Mechanism of Action | Thrombopoietin Receptor Agonists |
Physiological Effect | Increased Megakaryocyte Maturation Increased Platelet Production |
Established Pharmacologic Class | Thrombopoietin Receptor Agonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for romiplostim Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for romiplostim Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2018-10-23 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for romiplostim Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2033-03-11 | Patent claims search |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2034-11-21 | Patent claims search |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2039-02-26 | Patent claims search |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2031-04-05 | Patent claims search |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2035-10-02 | Patent claims search |
Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | See Plans and Pricing | 2039-12-21 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for romiplostim
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | PA01003873 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 0024782 | See Plans and Pricing |
China | 1331701 | See Plans and Pricing |
Slovakia | 4962001 | See Plans and Pricing |
Japan | 2007105044 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 0024770 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for romiplostim
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
SZ 25/2009 | Austria | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM |
CA 2009 00025 | Denmark | See Plans and Pricing | |
C200900026 | Spain | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM; NATIONAL AUTHORISATION NUMBER: 1/08/497/001-002; DATE OF AUTHORISATION: 20090204; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): UEEU/1/08/497/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20090204 |
PA2009006 | Lithuania | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
SPC/GB09/035 | United Kingdom | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM; REGISTERED: UK EU/1/08/497/001 20090206; UK EU/1/08/497/002 20090206 |
25/2009 | Austria | See Plans and Pricing | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.